



This Page Blank (uspto)

This Page Blank (uspto)



```

chain nodes :
  13 15 16 17 19 24
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
  5-8 13-19 15-19 15-24 16-17
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
  15-19 15-24 16-17
exact bonds :
  5-8 13-19
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
  containing 1 : 7 :
  
```


G1:O,N

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 22:CLASS 23:CLASS 24:Atom
  
```

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10673100.str



chain nodes :

13 16 17 19 21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-8 13-16 16-17 19-21 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

13-16 16-17 19-21 21-22

exact bonds :

5-8

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS 14:CLASS 16:CLASS 17:Atom 19:CLASS 20:CLASS

21:CLASS 22:Atom

Generic attributes :

17:

10/673,100

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 17: Limited
N,N0
C,C5

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:47:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1683 TO ITERATE

59.4% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 31200 TO 36120

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10673100 (broad).str



chain nodes :
 13 16 17 18 20 22
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12
 chain bonds :
 5-8 13-22 16-17 16-22 18-20
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
 exact/norm bonds :
 16-17 16-22 18-20
 exact bonds :
 5-8 13-22
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
 isolated ring systems :
 containing 1 : 7 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:CLASS 19:CLASS
 20:CLASS 22:CLASS

Generic attributes :

17:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 17: Limited
N,N0
C,C5

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam

SAMPLE SEARCH INITIATED 17:49:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1679 TO ITERATE

59.6% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 31123 TO 36037
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l3 sss ful

FULL SEARCH INITIATED 17:50:57 FILE 'REGISTRY'


FULL SCREEN SEARCH COMPLETED - 34158 TO ITERATE

100.0% PROCESSED 34158 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L3

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10673100 (a).str



chain nodes :

13 15 16 17 18 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-8 13-20 15-16 15-20 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

15-16 15-20 17-18

exact bonds :

5-8 13-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS 15:CLASS 16:Atom 17:CLASS 18:CLASS 20:CLASS

24:CLASS 25:CLASS

Generic attributes :

10/673,100

16:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 16: Limited
N,N0
C,C5

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss sam

SAMPLE SEARCH INITIATED 17:56:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1679 TO ITERATE


59.6% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 31123 TO 36037
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10673100 (b).str



chain nodes :

13 15 16 17 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-8 13-19 15-19 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

15-19 16-17

exact bonds :

5-8 13-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 22:CLASS

23:CLASS

L8 STRUCTURE UPLOADED

=> d l8

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l8 sss sam

SAMPLE SEARCH INITIATED 17:57:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1678 TO ITERATE

59.6% PROCESSED 1000 ITERATIONS

39 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 31103 TO 36017

PROJECTED ANSWERS: 823 TO 1793

L9 39 SEA SSS SAM L8

=> => d his

(FILE 'HOME' ENTERED AT 17:46:21 ON 01 JUL 2004)

FILE 'REGISTRY' ENTERED AT 17:46:42 ON 01 JUL 2004

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 STRUCTURE UPLOADED

L4 0 S L3 SSS SAM

L5 0 S L3 SSS FUL

L6 STRUCTURE UPLOADED

L7 0 S L6 SSS SAM

L8 STRUCTURE UPLOADED

L9 39 S L8 SSS SAM

L10 STRUCTURE UPLOADED

L11 3 S L10 SSS SAM

L12 143 S L10 SSS FUL

=> => s l12

L13 18 L12

=> d l13 1-18 bib,ab,hitstr

L13 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:269865 CAPLUS

DN 140:303540

TI Preparation of 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridines as bradykinin B1 antagonists

IN Kuduk, Scott D.; Bock, Mark G.; Feng, Dong-Mei; Wai, Jenny Miu-Chun

PA USA

SO U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004063761	A1	20040401	US 2003-634966	20030805
PRAI	US 2002-401454P	P	20020806		
OS	MARPAT 140:303540				

AB The title compds. [I; X, Y = CH; or one of X and Y = CH and the other = N; R1, R2 = H, alkyl; R3 = H, alkyl, haloalkyl, substituted alkyl; R4 = H, NO2, halo, etc.; R5 = cycloalkyl substituted with 1-2 F atoms, CHF2, CH2CF3, C2F5, CH2CH2CF3; R61 = (un)substituted alkyl, cycloalkyl, halo, etc.; R62, R63 = H, R61 (with the proviso that not more than one of R61, R62 and R63 is heterocycle); R7 = H, CN, NO2, etc.], useful as bradykinin B1 antagonist compds. for the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway, were prepared and formulated. E.g., a 4-step synthesis of II, starting from 2-amino-4-methyl-3-nitropyridine and 2-fluoro-4-bromobenzyl bromide, was given.


IT **676444-59-0P 676444-60-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridines as bradykinin B1 antagonists for treating or preventing pain and inflammation)

RN 676444-59-0 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[4-methyl-2-[[[2'-(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 676444-60-3 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[4-methyl-2-[[[2'-(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676444-59-0


CMF C23 H23 F3 N4 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L13 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:182533 CAPLUS
 DN 140:235608
 TI Preparation of 2-(biarylalkyl)amino-3-(cyanoalkanoylamino)pyridines as
 bradykinin B1 antagonists for treating pain and inflammation
 IN Kuduk, Scott D.; Bock, Mark G.; Feng, Dong-mei; Su, Dai-shi; Wai, Jenny
 Miu-chun
 PA USA
 SO U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004044041	A1	20040304	US 2003-634426	20030805
PRAI	US 2002-401386P	P	20020806		
OS	MARPAT 140:235608				

AB The title compds. [I; m = 1-4; X, Y = CH, or one is CH and the other is N; R1, R2 = H, alkyl; R3 = H, alkyl, haloalkyl, etc.; R4 = H, NO2, halo, etc.; R51, R52 = H, Me; or R51 and R52 together complete cycloalkyl ring; R61 = (un)substituted alkyl, cycloalkyl, alkenyl, etc.; R62, R63 = H, R61; with the proviso that not more than one of R61, R62 and R63 = heterocycle; R7 = H, alkyl, cycloalkyl, aryl, arylalkyl] which are bradykinin B1 antagonist compds. useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway, were prepared and formulated. E.g., a multi-step synthesis of II (starting from 4'-methyl-2-biphenylcarboxylic acid), was given. The compds. I have affinity for B1 receptor with IC50 values of < 5 μ M.


IT **668473-00-5P 668473-01-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(biarylalkyl)amino-3-(cyanoalkanoylamino)pyridines as bradykinin B1 antagonists)

RN 668473-00-5 CAPLUS

CN Acetamide, 2-cyano-N-[4-methyl-2-[[[2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 668473-01-6 CAPLUS


CN Acetamide, 2-cyano-N-[4-methyl-2-[[[2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10/673,100

CM 1

CRN 668473-00-5


CMF C23 H23 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L13 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:142809 CAPLUS
 DN 140:199328
 TI Preparation of 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives
 as bradykinin receptor B1 antagonists
 IN Kuduk, Scott D.; Bock, Mark G.; Feng, Dong-mei; Wai, Jenny Miu-chun
 PA USA
 SO U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004034064	A1	20040219	US 2003-634402	20030805
PRAI	US 2002-401462P	P	20020806		
OS	MARPAT 140:199328				

AB The title compds. (I) [both X and Y = CH, or one is CH and the other is N; R1, R2 = H, alkyl; R3 = H, (un)substituted alkyl; R4 = H, NO2, halo, etc.; R5 = alkyl, cycloalkyl, Me substituted with cycloalkyl, aryl, etc.; R6a = (un)substituted alkyl, cycloalkyl, halo, OCF3, etc.; R6b, R6c = H, R6a (with the proviso that not more than one of R6a, R6b, and R6c is a heterocycle); R7 = H, CN, NO2, halo, etc.] or pharmaceutically acceptable salts thereof are prepared and formulated. E.g., a multi-step synthesis of II (starting from 4'-methyl-2-biphenylcarboxylic acid), was given. The compds. I are bradykinin receptor B1 antagonists [IC50 of < 5 µM] and useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin receptor B1 pathway. More specifically these symptoms include (1) osteoarthritis, repetitive motion pain, dental pain, cancer pain, myofascial pain, muscular injury pain, fibromyalgia pain, and perioperative pain and (2) inflammatory pain caused by chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, rhinitis, pancreatitis, cystitis (interstitial cystitis), uveitis, inflammatory skin disorders, rheumatoid arthritis, edema resulting from trauma associated with burns, sprains or fracture, postsurgical intervention, osteoarthritis, rheumatic disease, tenosynovitis, or gout, (3) pain associated with angina or menstruation, and (4) pain caused by pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis, adult respiratory distress syndrome, bronchitis, allergic rhinitis, vasomotor rhinitis, liver disease, multiple sclerosis, atherosclerosis, Alzheimer's disease, septic shock, cerebral edema, headache, migraine, closed head trauma, irritable bowel syndrome, or nephritis. These compds. are also useful for the treatment of diabetic vasculopathy, post capillary resistance, diabetic symptoms associated with insulinitis, psoriasis, eczema, spasms of the gastrointestinal tract or uterus, Crohn's disease, ulcerative colitis, or pancreatitis.


IT **661483-46-1P 661483-47-2P 661484-03-3P**
661484-04-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (biarylalkyl)amino(alkanoylamino)pyridines as bradykinin receptor B1 antagonists for treatment or prevention of symptoms associated with bradykinin receptor B1 pathway)

RN 661483-46-1 CAPLUS

CN Butanamide, N-[2-[[[2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 661483-47-2 CAPLUS

CN Butanamide, N-[2-[[[2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 661483-46-1


CMF C23 H26 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 661484-03-3 CAPLUS


CN Butanamide, N-[2-[[[2'-[[[1,1-dimethylethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 661484-04-4 CAPLUS
 CN Butanamide, N-[2-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-pyridinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 661484-03-3
 CMF C26 H32 N4 O3 S





CM 2

CRN 76-05-1
 CMF C2 H F3 O2




L13 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:894437 CAPLUS
 DN 138:82921
 TI Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of
 N-[[2'-[[[4,5-Dimethyl-3-isoxazolyl]amino]sulfonyl]-4-(2-oxazolyl)[1,1'-
 biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a Highly
 Potent and Orally Active ETA Selective Antagonist
 AU Murugesan, Natesan; Gu, Zhengxiang; Spergel, Steven; Young, Marian; Chen,
 Ping; Mathur, Arvind; Leith, Leslie; Hermsmeier, Mark; Liu, Eddie C.-K.;
 Zhang, Rongan; Bird, Eileen; Waldron, Tom; Marino, Anthony; Koplowitz,
 Barry; Humphreys, W. Griffith; Chong, Saeho; Morrison, Richard A.; Webb,
 Maria L.; Moreland, Suzanne; Trippodo, Nick; Barrish, Joel C.
 CS Departments of Chemistry, Cardiovascular Agents, Cardiovascular
 Biochemistry and Pharmacology, Metabolism and Pharmacokinetics,
 Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ,
 08543-5400, USA
 SO Journal of Medicinal Chemistry (2003), 46(1), 125-137
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 138:82921
 AB We have previously disclosed the selective ETA receptor antagonist
 N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide
 (BMS-193884) as a clin. development candidate. Addnl. SAR studies at the
 2'-position of the compound led to the identification of several analogs
 with improved binding affinity as well as selectivity for the ETA
 receptor. Following the discovery that a 3-amino-isoxazole group displays
 significantly improved metabolic stability in comparison to its
 5-regioisomer, the 3-amino-isoxazole group was combined with the optimal
 2'-substituent leading to 16a (BMS-207940). One of compds. is an
 extremely potent (ETA Ki = 10 pM) and selective (80000-fold for ETA vs
 ETB) antagonist. It is also 150-fold more potent and >6-fold more
 selective than BMS-193884. The bioavailability of 16a was 100% in rats
 and the systemic clearance and volume of distribution are higher than that
 of BMS-193884. In rats, i.v. 16a blocks big ET pressor responses with
 30-fold greater potency than BMS-193884. After oral dosing at 3
 µmol/kg, 16a displays enhanced duration relative to BMS-193884.
 IT **195445-34-2P 195446-49-2P**
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (further studies of biphenylsulfonamide endothelin receptor
 antagonists)
 RN 195445-34-2 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-
 oxazolyl)-2'-[(4-pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 195446-49-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'--[[(5-methyl-3-isoxazolyl)amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L13 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:755214 CAPLUS
 DN 137:263024
 TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
 IN Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang
 PA Bristol-Myers Squibb Co., USA
 SO U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143024	A1	20021003	US 2000-737201	20001214 ←
	US 6638937	B2	20031028		
	US 2004106833	A1	20040603	US 2003-673100	20030926 ← <i>Appl.</i>
PRAI	US 1998-91847P	P	19980706		
	US 1999-345392	B2	19990701		
	US 1999-464037	B2	19991215		
	US 2000-481197	B2	20000111		
	US 2000-513779	A2	20000225		
	US 2000-604322	A2	20000626		
	US 2000-643640	B2	20000822		
	US 2000-737201	A3	20001214		

OS MARPAT 137:263024

AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO₂, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO₂, etc; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC₆H₄CH₂OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonylphenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

IT **254738-21-1P**, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
254739-37-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl-
254739-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]-
254739-65-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-methyl-4-quinolinyl)oxy]methyl]-
254739-66-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-4-quinolinyl)oxy]methyl]-
254739-67-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]-
254739-68-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-propyl-4-quinolinyl)oxy]methyl]-
254739-70-3P,

[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254739-71-4P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- **254739-77-0P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254739-85-0P**, 3-Pyridinecarboxylic acid, 2'-[[2'-[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]- **254739-90-7P**, 3-Pyridinecarboxamide, 2'-[[2'-[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]-N-methyl- **254739-91-8P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254739-92-9P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254739-94-1P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(methoxymethyl)- **254740-05-1P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254740-06-2P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]-2'-(trifluoromethyl)- **254740-12-0P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254740-36-8P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(3,3,3-trifluoropropyl)- **254740-59-5P**, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl)oxy)methyl]-N-(3-methyl-5-isoxazolyl)- **254742-06-8P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-methyl- **254742-10-4P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- **254742-39-7P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-methyl-4-quinolinyl)oxy)methyl]- **254742-41-1P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254742-43-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- **254742-45-5P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-propyl-4-quinolinyl)oxy)methyl]- **254742-47-7P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254742-49-9P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- **254742-60-4P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- **254742-69-3P**, 3-Pyridinecarboxylic acid, 2'-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]- **254742-75-1P**, 3-Pyridinecarboxamide, 2'-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]-N-methyl- **254742-76-2P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254742-77-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-

pyridinyl)oxy)methyl]- **254742-79-5P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(methoxymethyl)- **254742-89-7P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy)methyl]- **254742-91-1P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy)methyl]-2'-(trifluoromethyl)- **254742-97-7P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-20-9P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(3,3,3-trifluoropropyl)- **254743-34-5P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-35-6P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-36-7P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-37-8P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-38-9P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-39-0P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-40-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-41-4P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-56-1P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-57-2P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-58-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(tetrahydro-2-furanyl)- **254743-66-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-67-4P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-68-5P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(tetrahydro-2-furanyl)- **254743-74-3P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-propyl- **254743-75-4P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-propyl- **254743-78-7P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-79-8P**, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-92-5P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- **254743-93-6P**, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-


4-pyridinyl)oxy)methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 254738-21-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'--[[(2-ethyl-4-quinolinyl)oxy)methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 254739-37-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'--[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-methyl- (9CI) (CA INDEX NAME)




RN 254739-41-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'--[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)



RN 254739-65-6 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-methyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-66-7 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-68-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-70-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254739-71-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254739-77-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-85-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 254739-90-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)



RN 254739-91-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-92-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 254739-94-1 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)



RN 254740-05-1 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-

[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254740-06-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254740-12-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254740-36-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'--[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254740-59-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'--[[2-ethyl-4-quinolinyl]oxy]methyl]-N-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 254742-06-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- (9CI) (CA INDEX NAME)




RN 254742-10-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-39-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-methyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-41-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-43-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-45-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-propyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-47-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-49-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-60-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-69-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 254742-75-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 254742-76-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-77-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[[[3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-79-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)




RN 254742-89-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[(2-ethyl-4-quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254742-97-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'--[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-20-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254743-34-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-35-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-36-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-37-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-38-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-39-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-40-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-41-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-56-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-57-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 254743-66-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)





RN 254743-67-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-68-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 254743-74-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'--[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-75-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-78-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)




RN 254743-79-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)



RN 254743-92-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)

RN 254743-93-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)


IT 254746-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254746-81-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



PAGE 2-A




IT **254745-61-4P**, [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- **254745-62-5P**, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- **254746-43-5P**, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl) [2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester **254746-44-6P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- **254746-45-7P** **254746-53-7P**, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl) [2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester **254746-54-8P**, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- **254746-71-9P**,

[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]-
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 254745-61-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[(2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)



RN 254745-62-5 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)



RN 254746-43-5 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl) [[2-[(trimethylsilyl)oxy]ethoxy)methyl]amino]sulfonyl]-2-[[(tetrahydro-2H-

pyran-2-yl)oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 254746-44-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[[(tetrahydro-2H-pyran-2-yl)oxy)methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 254746-45-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(tetrahydro-2H-pyran-2-yl)oxy)methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 254746-53-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl) [[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 254746-54-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 254746-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:107924 CAPLUS

DN 136:167692

TI Preparation of new biphenyl and biphenyl-analogous compounds as integrin antagonists

IN Albers, Markus; Urbahns, Klaus; Vaupel, Andrea; Harter, Michael; Schmidt, Delf; Stelte-Ludwig, Beatrix; Gerdes, Christoph; Stahl, Elke; Keldenich, Jorg; Brueggemeier, Ulf; Lustig, Klemens

PA Bayer Aktiengesellschaft, Germany

SO U.S. Pat. Appl. Publ., 256 pp., Division of U.S. Ser. No. 464,237.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002016461	A1	20020207	US 2001-828514	20010406
	US 6677360	B2	20040113		
	US 6420396	B1	20020716	US 1999-464237	19991215
	US 2004030132	A1	20040212	US 2002-285073	20021031
PRAI	US 1998-172225P	P	19981216		
	US 1999-464237	A3	19991215		
	US 1999-172217P	P	19991019		
	US 2001-828514	A3	20010406		

OS MARPAT 136:167692

AB Biphenyl compounds. R1O2CCHR2-U-V-A-B-W-NR3-C-R4 [R1 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl; R2 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, alkenyl, alkynyl, -NR2'SO2R2'', -NR2'CO2R2'', -NR2'COR2'', -NR2'CONR2'2, -NR2'CSNR2'2 (R2' has same definition as R1 and R2'' has same definition as R1 except it is not H); U or W is a direct bond or (un)substituted alkylene; V = (un)substituted alkylene, -NR2'CO- or NR2'SO2-; A and B = (un)substituted 1,3- or 1,4-bridging phenylene group or a 2,4- or 2,5-bridging thienylene group, each of which may have substituents; C is a direct bond, CMe(:X-R5)-Y-N(R6)- (R5 is absent, H, (un)substituted alkyl or cycloalkyl, NO2, acyl, carboxylic or carboxylate group or is connected to R3, Y, R4 or R6, if present; R6 is H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, an alkylamine or alkylamide residue, or is connected to one of R3, R4, Y, or R5, if present, to form a heterocyclic ring system; X = CHNO2, CHCN, O, N or S; Y is a direct bond or (un)substituted alkylene or alkylene group) or 3,4-dioxo-1,2-cyclobutenediyl-NR6-; R3, R4 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, an alkylamine or alkylamide residue, or is connected to one of R4 (or R3), Y, R5 or R6, if present, to form a heterocyclic ring system] were prepared as integrin antagonists. For example, (2R,S)-3-[3-(pyridin-3-ylmethylureido)biphenyl-4-yl]-2-[2,4,6-trimethylbenzenesulfonylamino]propanoic acid, prepared by reactions of resin-bound (2R,S)-3-(4-bromophenyl)-2-(9-fluorenylmethoxycarbonylamino)propanoic acid with sulfonylating, boronic acid, and amine reagents (mesitylenesulfonyl chloride, 3-nitrobenzeneboronic acid, and 2-aminomethylpyridine), showed IC50 = 5 nM for binding to the α v β 3 receptor and IC50 = 480 nM in the smooth muscle cell migration test. Thus, the invention compounds are useful for the inhibition of angiogenesis and/or for therapy and prophylaxis of cancer, osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis, rheumatoid arthritis, and ophthalmic disorders (no data).

IT 276262-14-7P 276262-30-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenyl amino acid analogs as integrin antagonists for inhibition of angiogenesis and treatment of cancer, osteolytic diseases, arteriosclerosis, restenosis, rheumatoid arthritis, and ophthalmic disorders)


RN 276262-14-7 CAPLUS

CN Benzenepropanoic acid, β -[[[4-methoxy-3'-[(2-pyridinylamino)methyl][1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 276262-30-7 CAPLUS


CN Benzenepropanoic acid, β -[[[3'-[(1H-benzimidazol-2-ylamino)methyl]-4-methoxy[1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L13 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:1479 CAPLUS
 DN 136:379462
 TI Biphenyls as potent vitronectin receptor antagonists
 AU Urbahns, Klaus; Harter, Michael; Albers, Markus; Schmidt, Delf;
 Stelte-Ludwig, Beatrix; Bruggemeier, Ulf; Vaupel, Andrea; Gerdes,
 Christoph
 CS Pharma Research Centre, Institute of Medicinal Chemistry, Bayer AG,
 Wuppertal, D-42096, Germany
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(2), 205-208
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Vitronectin receptor ($\alpha V\beta 3$) antagonism has been implicated as a
 mechanism for the treatment of restenosis following balloon angioplasty.
 In this work the authors present results from screening of a focused
 combinatorial library based on a biphenyl moiety. Our SAR studies led to
 the identification of compds. with subnanomolar activity, selectivity
 towards the related GPIIb/IIIa receptor and functional activity on human
 smooth muscle cell migration.
 IT **276262-14-7P 276262-30-7P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (biphenyls as potent vitronectin receptor antagonists in relation to
 activity towards GPIIb/IIIa and restenosis treatment)
 RN 276262-14-7 CAPLUS
 CN Benzenepropanoic acid, β -[[[4-methoxy-3'-[(2-
 pyridinylamino)methyl][1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA
 INDEX NAME)



RN 276262-30-7 CAPLUS
 CN Benzenepropanoic acid, β -[[[3'-[(1H-benzimidazol-2-ylamino)methyl]-4-
 methoxy[1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L13 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:713360 CAPLUS
 DN 135:273076
 TI Sulfur substituted phenyldifluoromethylphosphonic acids as PTP-1B inhibitors
 IN Li, Chun Sing; Lau, Cheuk K.; Therien, Michel; Gauthier, Jacques Y.; Bayly, Christopher; Dufresne, Claude; Fortin, Rejean; Leblanc, Yves; Roy, Patrick; Wang, Zhaoyin
 PA Merck Frosst Canada & Co., Can.
 SO PCT Int. Appl., 337 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070753	A1	20010927	WO 2001-CA373	20010321
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002002149	A1	20020103	US 2001-813499	20010321
	US 6465444	B2	20021015		
	US 2002091104	A1	20020711	US 2001-813489	20010321
	US 6498151	B2	20021224		
	EP 1268494	A1	20030102	EP 2001-916791	20010321
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003528106	T2	20030924	JP 2001-568954	20010321
PRAI	US 2000-191369P	P	20000322		
	WO 2001-CA373	W	20010321		

OS MARPAT 135:273076

AB The invention encompasses the novel class of I (e.g. 4'-[4-(difluorophosphonomethyl)benzylthiomethyl]-4-(3-methylbutoxy)biphenyl-3-ylphosphonic acid), or a pharmaceutically acceptable salt or prodrug thereof, which are inhibitors of the protein tyrosine phosphatase-1B (PTP-1B) enzyme (no data). The invention also encompasses pharmaceutical compns. and methods of treating or preventing PTP-1B mediated diseases, including diabetes. In I, X1 and X2 = independently H, OH, halogen, CN, CO2H, CO2C1-6alkyl, CO2C2-6alkenyl, OC1-6alkyl, OC2-6alkenyl, C(O)C1-6alkyl, C(O)C2-6alkenyl, OC(O)C1-6alkyl, OC(O)C2-6alkenyl, S(O)xC1-6alkyl, S(O)xC2-6alkenyl, C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, S(O)2NR1R2, C(O)NR1R2, and NR1R2, wherein each alkyl group and each alkenyl group in each substituent is optionally substituted. X = 0-2; R5 = H. R1 and R2 independently = H and C1-4alkyl, wherein said alkyl substituents are optionally substituted with 1-9 halogen atoms; Y1 = bond, C1-6 alkylene group, and C2-6 alkenylene group, wherein said alkylene group and said alkenylene group are optionally substituted. R = C1-10 alkyl, C2-10alkenyl, C2-10alkadienyl, C2-10alkynyl, Ar1, and Het1, wherein said alkyl, alkenyl, alkadienyl, and alkynyl are optionally substituted; Het1 = a 5-10 membered aromatic ring system comprising 1 ring or 2 rings fused together and 1-4 heteroatoms selected from O, N, S(O)x, and combinations thereof, and 0-2 carbonyl groups, wherein one of said fused

rings is optionally a benzene ring, and said Het1 is optionally substituted; Ar1 = Ph or naphthyl, optionally substituted. Although the methods of preparation are not claimed, 209 example preps. are included.


IT 362529-88-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; sulfur substituted phenyldifluoromethylphosphonic acids as PTP-1B inhibitors)

RN 362529-88-2 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4'-[[tetrahydro-2H-pyran-2-yl)oxy]methyl]-
(9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:453059 CAPLUS

DN 135:46172

TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.

IN Murugesan, Natesan; Tellev, John E.; Macor, John E.; Gu, Zhengxiang

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 287 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044239	A2	20010621	WO 2000-US33730	20001213
	WO 2001044239	A3	20011101		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP	1237888	A2	20020911	EP 2000-984282	20001213
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
JP	2003520785	T2	20030708	JP 2001-544729	20001213
PRAI	US 1999-464037	A	19991215		
	US 2000-481197	A	20000111		
	US 2000-513779	A	20000225		
	US 2000-604322	A	20000626		
	US 2000-643640	A	20000822		
	WO 2000-US33730	W	20001213		

Parent appln

OS MARPAT 135:46172

AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)](2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give II.

IT 254738-21-1P 254739-37-2P 254739-41-8P
 254739-65-6P 254739-66-7P 254739-67-8P
 254739-68-9P 254739-70-3P 254739-71-4P
 254739-77-0P 254739-85-0P 254739-90-7P
 254739-91-8P 254739-92-9P 254739-94-1P
 254740-05-1P 254740-06-2P 254740-12-0P
 254740-36-8P 254740-59-5P 254742-06-8P
 254742-10-4P 254742-39-7P 254742-41-1P
 254742-43-3P 254742-45-5P 254742-47-7P


254742-49-9P 254742-60-4P 254742-69-3P
 254742-75-1P 254742-76-2P 254742-77-3P
 254742-79-5P 254742-89-7P 254742-91-1P
 254742-97-7P 254743-20-9P 254743-34-5P
 254743-35-6P 254743-36-7P 254743-37-8P
 254743-38-9P 254743-39-0P 254743-40-3P
 254743-41-4P 254743-56-1P 254743-57-2P
 254743-58-3P 254743-66-3P 254743-67-4P
 254743-68-5P 254743-74-3P 254743-75-4P
 254743-78-7P 254743-79-8P 254743-92-5P
 254743-93-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 254738-21-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 254739-37-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- (9CI) (CA INDEX NAME)




RN 254739-41-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-65-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-methyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-66-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-methyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-68-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-70-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-71-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 254739-77-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-4-quinolinyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 254739-85-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- (9CI)
(CA INDEX NAME)




RN 254739-90-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)



RN 254739-91-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-92-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 254739-94-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)




RN 254740-05-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254740-06-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254740-12-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254740-36-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254740-59-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-N-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 254742-06-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- (9CI) (CA INDEX NAME)




RN 254742-10-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-39-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[(2-methyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-41-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-43-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-45-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-propyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-47-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'--[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-49-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'--[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'--[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-60-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-69-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 254742-75-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 254742-76-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-77-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[[[3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-79-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)




RN 254742-89-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254742-97-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-20-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254743-34-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'--[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-35-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'--[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-36-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-37-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-38-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-
[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-39-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-
dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-
(9CI) (CA INDEX NAME)




RN 254743-40-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-41-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-56-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-57-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI)
(CA INDEX NAME)




RN 254743-66-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)





RN 254743-67-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-68-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 254743-74-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-75-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-78-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)




RN 254743-79-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)






RN 254743-92-5 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
 (CA INDEX NAME)



RN 254743-93-6 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
 (CA INDEX NAME)




IT **254746-81-1**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-isoxazolyl biphenylsulfonamides and related compds. as
 dual angiotensin II and endothelin receptor antagonists)
 RN 254746-81-1 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA
 INDEX NAME)



IT 254745-61-4P 254745-62-5P 254746-43-5P
 254746-44-6P 254746-45-7P 254746-53-7P
 254746-54-8P 254746-71-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N-isoxazolyl biphenylsulfonamides and related compds. as
 dual angiotensin II and endothelin receptor antagonists)


RN 254745-61-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[2-ethyl-4-
 quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254746-44-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 254746-45-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 254746-53-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl) [[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 254746-54-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 254746-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:421093 CAPLUS

DN 133:43809

TI Preparation of new biphenyl and biphenyl-analogous compounds as integrin antagonists

IN Albers, Markus; Urbahns, Klaus; Vaupel, Andrea; Harter, Michael; Schmidt, Delf; Stelte-ludwig, Beatrix; Gerdes, Christoph; Stahl, Elke; Keldenich, Jorg; Bruggemeier, Ulf; Lustig, Klemens

PA Bayer Aktiengesellschaft, Germany; et al.

SO PCT Int. Appl., 360 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035864	A1	20000622	WO 1999-EP9843	19991213
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1140809	A1	20011010	EP 1999-967934	19991213
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9916367	A	20011030	BR 1999-16367	19991213
	TR 200102498	T2	20020221	TR 2001-200102498	19991213
	EE 200100317	A	20020815	EE 2001-317	19991213
	JP 2002532465	T2	20021002	JP 2000-588126	19991213
	NZ 512339	A	20030328	NZ 1999-512339	19991213
	AU 761407	B2	20030605	AU 2000-24312	19991213
	ZA 2001014432	A	20020530	ZA 2001-14432	20010530
	BG 105574	A	20020131	BG 2001-105574	20010607
	NO 2001002975	A	20010813	NO 2001-2975	20010615
	HR 2001000531	A1	20020831	HR 2001-531	20010716
PRAI	US 1998-213381	A	19981216		
	WO 1999-EP9843	W	19991213		

OS MARPAT 133:43809

AB Biphenyl compds. R1O2CCHR2-U-V-A-B-W-NR3-C-R4 [R1 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl; R2 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, alkenyl, alkynyl, -NR2'SO2R2'', -NR2'CO2R2'', -NR2'COR2'', -NR2'CONR2'2, -NR2'CSNR2'2 (R2' has same definition as R1 and R2'' has same definition as R1 except it is not H); U or W is a direct bond or (un)substituted alkylene; V = (un)substituted alkylene, -NR2'CO- or NR2'SO2-; A and B = (un)substituted 1,3- or 1,4-bridging phenylene group or a 2,4- or 2,5-bridging thienylene group, each of which may have substituents; C is a direct bond, CMe(:X-R5)-Y-N(R6)- (R5 is absent, H, (un)substituted alkyl or cycloalkyl, NO2, acyl, carboxylic or carboxylate group or is connected to R3, Y, R4 or R6, if present; R6 is H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, an alkylamine or alkylamide residue, or is connected to one of R3, R4, Y, or R5, if present, to form a heterocyclic ring system; X = CHNO2, CHCN, O, N or S; Y is a direct bond or (un)substituted alkylene or alkyne group) or 3,4-dioxo-1,2-


cyclobutenediyl-NR6-; R3, R4 = H, (un)substituted alkyl, cycloalkyl, aryl, or (un)saturated heterocyclyl, an alkylamine or alkylamide residue, or is connected to one of R4 (or R3), Y, R5 or R6, if present, to form a heterocyclic ring system] were prepared as integrin antagonists. Thus, (2R,S)-3-[3-(pyridin-3-ylmethylureido)biphenyl-4-yl]-2-[2,4,6-trimethylbenzenesulfonylamino]propanoic acid, prepared by reactions of resin-bound (2R,S)-3-(4-bromophenyl)-2-(9-fluorenylmethoxycarbonylamino)propanoic acid with sulfonylating, boronic acid, and amine reagents (mesitylenesulfonyl chloride, 3-nitrobenzeneboronic acid, and 2-aminomethylpyridine), showed IC50 = 5 nM for binding to the α v β 3 receptor and IC50 = 480 nM in the smooth muscle cell migration test.

IT 276262-14-7P 276262-30-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new biphenyl and biphenyl-analogous compds. as integrin antagonists)


RN 276262-14-7 CAPLUS

CN Benzenepropanoic acid, β -[[[4-methoxy-3'-[(2-pyridinylamino)methyl][1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 276262-30-7 CAPLUS

CN Benzenepropanoic acid, β -[[[3'-[(1H-benzimidazol-2-ylamino)methyl]-4-methoxy[1,1'-biphenyl]-3-yl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

This Page Blank (uspto)

This Page Blank (uspto)

L13 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:34745 CAPLUS
 DN 132:93309
 TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
 IN Murugesan, Natesan; Tellev, John E.; Macor, John E.; Gu, Zhengxiang
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 283 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

Same Inv. Entity.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001389	A1	20000113	WO 1999-US15063	19990701
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336714	AA	20000113	CA 1999-2336714	19990701
AU 9950888	A1	20000124	AU 1999-50888	19990701
AU 767456	B2	20031113		
EP 1094816	A1	20010502	EP 1999-935406	19990701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9911621	A	20011016	BR 1999-11621	19990701
TR 200100149	T2	20011022	TR 2001-200100149	19990701
EE 200100006	A	20020617	EE 2001-6	19990701
JP 2002519380	T2	20020702	JP 2000-557835	19990701
NZ 508118	A	20030725	NZ 1999-508118	19990701
ZA 2000006772	A	20020220	ZA 2000-6772	20001120
LT 4854	B	20011126	LT 2000-123	20001222
NO 2001000062	A	20010305	NO 2001-62	20010105
BG 105205	A	20010928	BG 2001-105205	20010131
LV 12639	B	20010920	LV 2001-17	20010205
PRAI US 1998-91847P	P	19980706	← <i>Same Prov. Appln.</i>	
WO 1999-US15063	W	19990701		
OS MARPAT 132:93309				
AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; with provisos), were prepared as dual angiotensin II and endothelin receptor antagonists (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)](2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide. This was brominated to give 4'-bromomethyl-N-(4,5-dimethyl-3-isoxazolyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide, which reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride followed by deprotection to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide.				
IT 254738-21-1P 254739-37-2P 254739-41-8P				
254739-65-6P 254739-66-7P 254739-67-8P				

254739-68-9P 254739-70-3P 254739-71-4P
 254739-77-0P 254739-85-0P 254739-90-7P
 254739-91-8P 254739-92-9P 254739-94-1P
 254740-05-1P 254740-06-2P 254740-12-0P
 254740-36-8P 254740-59-5P 254742-06-8P
 254742-10-4P 254742-39-7P 254742-41-1P
 254742-43-3P 254742-45-5P 254742-47-7P
 254742-49-9P 254742-60-4P 254742-69-3P
 254742-75-1P 254742-76-2P 254742-77-3P
 254742-79-5P 254742-89-7P 254742-91-1P
 254742-97-7P 254743-20-9P 254743-34-5P
 254743-35-6P 254743-36-7P 254743-37-8P
 254743-38-9P 254743-39-0P 254743-40-3P
 254743-41-4P 254743-56-1P 254743-57-2P
 254743-58-3P 254743-66-3P 254743-67-4P
 254743-68-5P 254743-74-3P 254743-75-4P
 254743-78-7P 254743-79-8P 254743-92-5P
 254743-93-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 254738-21-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 254739-37-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- (9CI) (CA INDEX NAME)




RN 254739-41-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-65-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-methyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-66-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-67-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-68-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-70-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-71-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-77-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-85-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- (9CI)
(CA INDEX NAME)




RN 254739-90-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)



RN 254739-91-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'--[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254739-92-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'--[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'--[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 254739-94-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)




RN 254740-05-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254740-06-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254740-12-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254740-36-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254740-59-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-N-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 254742-06-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy)methyl]-2'-methyl- (9CI) (CA INDEX NAME)]




RN 254742-10-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)]




RN 254742-39-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-methyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-41-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-43-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-45-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'--[[2-propyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-47-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidiny)methyl]-4'-[[2-ethyl-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-49-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidiny)methyl]-4'-[[2-ethyl-5,6,7,8-tetrahydro-4-quinolinyloxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-60-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254742-69-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[[2'-[[4,5-dimethyl-3-isoxazolyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]propylamino]- (9CI) (CA INDEX NAME)




RN 254742-75-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 254742-76-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-77-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[[[3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[[3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-79-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- (9CI)
(CA INDEX NAME)




RN 254742-89-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[[(2-ethyl-4-quinolinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254742-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-ethyl-4-quinolinyl]oxy]methyl]-2'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 254742-97-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-20-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 254743-34-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-35-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-36-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-37-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-38-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-39-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-40-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-41-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 254743-56-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-57-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 254743-66-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)





RN 254743-67-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- (9CI)
(CA INDEX NAME)




RN 254743-68-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 254743-74-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-75-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- (9CI) (CA INDEX NAME)




RN 254743-78-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)




RN 254743-79-8 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-(9CI) (CA INDEX NAME)



RN 254743-92-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)

RN 254743-93-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[3-methoxy-2,6-dimethyl-4-pyridinyl]oxy]methyl]- (9CI)
(CA INDEX NAME)




IT 254746-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254746-81-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)




IT 254745-61-4P 254745-62-5P 254746-43-5P
 254746-44-6P 254746-45-7P 254746-53-7P
 254746-54-8P 254746-71-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-isoxazolyloxy biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)


RN 254745-61-4 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[2-ethyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 254745-62-5 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-ethyl-4-quinolinyl)oxy)methyl]-
(9CI) (CA INDEX NAME)




RN 254746-43-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[2-ethyl-4-quinolinyl)oxy)methyl]-
(9CI) (CA INDEX NAME)




RN 254746-44-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 254746-45-7 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)




RN 254746-53-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[[3,4-dimethyl-5-isoxazolyl][2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 254746-54-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 254746-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:788746 CAPLUS
 DN 130:52406
 TI Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
 IN Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
 PA Bristol-Myers Squibb Co., USA
 SO U.S., 107 pp., Cont.-in-part of U.S. Ser. No. 754,715, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

Diff. Own Entity.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5846990	A	19981208	US 1997-799616	19970213
	TW 517057	B	20030111	TW 1997-86101898	19970218
	ZA 9701423	A	19980819	ZA 1997-1423	19970219
	CA 2240043	AA	19970821	CA 1997-2240043	19970220
	WO 9729748	A1	19970821	WO 1997-US3956	19970220
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9722098	A1	19970902	AU 1997-22098	19970220
	AU 720458	B2	20000601		
	EP 921800	A1	19990616	EP 1997-915055	19970220
	EP 921800	B1	20040414		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002500619	T2	20020108	JP 1997-529620	19970220
	AT 264324	E	20040415	AT 1997-915055	19970220
PRAI	US 1995-493331	B2	19950724		
	US 1996-603975	B1	19960220		
	US 1996-754715	B2	19961121		
	US 1997-799616	A	19970213		
	WO 1997-US3956	W	19970220		
OS	MARPAT 130:52406				
AB	Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.				
IT	195445-14-8P	195445-34-2P	195446-43-6P		
	195446-45-8P	195446-47-0P	195446-49-2P		
	195446-50-5P	195446-51-6P	195446-52-7P		

195446-53-8P 195446-54-9P 195446-55-0P

195446-56-1P 195446-57-2P 195446-58-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)


RN 195445-14-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 195445-34-2 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(4-pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 195446-43-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[[1-(1,1-dimethylethyl)-3-methyl-1H-pyrazol-5-yl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-45-8 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(1H-pyrazol-3-ylamino)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 195446-47-0 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(1H-1,2,4-triazol-3-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 195446-49-2 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[5-methyl-3-isoxazolyl)amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-50-5 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[(4-cyano-1H-pyrazol-3-yl) amino]methyl]-
 N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-51-6 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(3,5-
 dimethylpyrazinyl) amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-52-7 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[4,6-dimethyl-2-pyrimidinyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-53-8 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[5-ethyl-1,3,4-thiadiazol-2-yl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 195446-54-9 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 2'--[(2-benzothiazolylamino)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 195446-55-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'--[[4-bromo-1H-pyrazol-3-yl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 195446-56-1 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 195446-57-2 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[6-methoxy-2-benzothiazolyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 195446-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'--[[[4-(4-chlorophenyl)-6-ethoxy-2-pyrimidinyl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:557640 CAPLUS
 DN 127:248103
 TI Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
 IN Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 325 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729748	A1	19970821	WO 1997-US3956	19970220
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5846990	A	19981208	US 1997-799616	19970213
	TW 517057	B	20030111	TW 1997-86101898	19970218
	ZA 9701423	A	19980819	ZA 1997-1423	19970219
	AU 9722098	A1	19970902	AU 1997-22098	19970220
	AU 720458	B2	20000601		
	EP 921800	A1	19990616	EP 1997-915055	19970220
	EP 921800	B1	20040414		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002500619	T2	20020108	JP 1997-529620	19970220
	AT 264324	E	20040415	AT 1997-915055	19970220
PRAI	US 1996-603975	A	19960220		
	US 1996-754715	A	19961121		
	US 1997-799616	A	19970213		
	US 1995-493331	B2	19950724		
	WO 1997-US3956	W	19970220		

OS MARPAT 127:248103

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclxyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.

IT 195445-14-8P 195445-34-2P 195446-43-6P
 195446-45-8P 195446-47-0P 195446-49-2P
 195446-50-5P 195446-51-6P 195446-52-7P
 195446-53-8P 195446-54-9P 195446-55-0P

195446-56-1P 195446-57-2P 195446-58-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)


RN 195445-14-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 195445-34-2 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(4-pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 195446-43-6 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[[1-(1,1-dimethylethyl)-3-methyl-1H-pyrazol-5-yl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-45-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(1H-pyrazol-3-ylamino)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 195446-47-0 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[(1H-1,2,4-triazol-3-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 195446-49-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(5-methyl-3-isoxazolyl)amino]methyl]-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-50-5 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[(4-cyano-1H-pyrazol-3-yl)amino]methyl]-
 N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-51-6 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(3,5-
 dimethylpyrazinyl)amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-52-7 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[4,6-dimethyl-2-pyrimidinyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 195446-53-8 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[5-ethyl-1,3,4-thiadiazol-2-yl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 195446-54-9 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 2'--[(2-benzothiazolylamino)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 195446-55-0 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'--[[4-bromo-1H-pyrazol-3-yl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 195446-56-1 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[[[5-(2-thienyl)-1H-pyrazol-3-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 195446-57-2 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[6-methoxy-2-benzothiazolyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 195446-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[[4-(4-chlorophenyl)-6-ethoxy-2-pyrimidinyl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L13 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:328687 CAPLUS
 DN 127:50587
 TI 3N-Methylbiphenylsulfonylurea and -carbamate substituted
 imidazo[4,5-b]pyridines. Potent antagonists of the ANG II AT1 receptors
 AU Heitsch, Holger; Becker, Reinhard H. A.; Kleemann, Heinz-Werner; Wagner,
 Adalbert
 CS Hoechst AG, HMR TA Cardiovascular Agents, Frankfurt/Main, D-65926, Germany
 SO Bioorganic & Medicinal Chemistry (1997), 5(4), 673-678
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier
 DT Journal
 LA English
 AB The synthesis and SAR study of imidazo[4,5-b]pyridine biphenyl
 sulfonylureas and -carbamates as highly potent AT1-selective ANG II
 receptor antagonists are described. Several members of this new class of
 antagonists efficiently inhibited the ANG II-induced pressor response in
 pithed rats after i.v. and intraduodenal (id) administration.
 IT **191172-73-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of biphenylsulfonylurea and -carbamate substituted
 imidazo[4,5-b]pyridines as antagonists of ANG II AT1 receptors)
 RN 191172-73-3 CAPLUS
 CN Propanamide, N-[[2'-[[[(dimethylamino)methylene]amino]sulfonyl][1,1'-
 biphenyl]-4-yl]methyl]-N-(4-methyl-3-nitro-2-pyridinyl)- (9CI) (CA INDEX
 NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:195555 CAPLUS
 DN 126:199563
 TI Preparation of thiazolinecarboxylic acid derivatives as angiotensin II antagonists
 IN Sakae, Shinya; Nishimura, Koji; Iguma, Kenichi; Tamura, Koichi; Amano, Hirotaka; Inoe, Satoshi
 PA Wakunaga Seiyaku Kk, Japan
 SO Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09020764	A2	19970121	JP 1995-170626	19950706
PRAI	JP 1995-170626		19950706		

OS MARPAT 126:199563


AB The title compds. I [R1 = H, COR2; R2 = alkyl, etc.; R3 = H, alkyl, etc.; X = OR4; R4 = H, carboxyl-protecting group, etc.; R7 = H, alkyl, etc.] are prepared 5-Butyl-2-cyclopropylcarbonylimino-3-[2'-(N-ethoxycarbonylsulfamoyl)biphenyl-4-yl]methylthiazoline-4-carboxylic acid showed IC50 of 0.99 nM against ileum contraction induced by angiotensin II.

IT **187614-22-8P**

RL: BYP (Byproduct); PREP (Preparation)
 (preparation of thiazolinecarboxylic acid derivs. as angiotensin II antagonists)

RN 187614-22-8 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(cyclopropylcarbonyl)[[2'-[[[1,1-dimethylethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:440544 CAPLUS

DN 125:114472

TI Preparation of pyrrolidinecarboxylic acid derivatives as angiotensin II antagonists.

IN Yanagisawa, Hiroaki; Kanazaki, Takuo; Amamya, Yosha; Furusawa, Juji; Mizuno, Makoto

PA Sankyo Co, Japan

SO Jpn. Kokai Tokkyo Koho, 259 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08092207	A2	19960409	JP 1995-189453	19950725
PRAI	JP 1994-174452		19940726		

OS MARPAT 125:114472

AB The title compds. [I; R1 = C1-6 alkyl, C2-6 alkenyl; R2 = (un)substituted C1-6 alkyl, C3-6 alkenyl or alkynyl, C3-6 cycloalkyl, etc.; R3 = H, protecting group; R4 = (protected) CO2H, tetrazolyl, SO2NHCOR5 (wherein R5 = C1-16 alkyl, C6-14 aryl; Y = O, bond), (un)substituted Ph; X = bond, O; Z1, Z2 = CO, SO2], useful as cardiovascular agents in treating hypertension, etc., at 0.5-30 mg/day in adults, are prepared. Acylation of trityl compound (2S,4S)-II (R = trityl, R3 = Me, R5 = H) with (BuCO)2O in pyridine gave valeryl compound (2S,4S)-II (R = trityl, R3 = Me, R5 = BuCO), which was treated with HOAc to give (2S,4S)-II (R = H, R3 = Me, R5 = BuCO) (III). Saponification of III gave the free acid II (R = R3 = H, R5 = BuCO).

IC50

of I against angiotensin II in rats were determined

IT 178866-61-0P 178866-62-1P 178866-71-2P

178866-72-3P 178866-73-4P 178866-74-5P

178866-75-6P 178866-76-7P 178866-77-8P

178866-78-9P 178866-85-8P 178866-86-9P

178866-89-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178866-61-0 CAPLUS

CN L-Proline, 4-[[[2'-[[[butoxycarbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(diphenylacetyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-62-1 CAPLUS

CN L-Proline, 4-[[[2'-[[(3-cyclopentyl-1-oxopropyl) amino] sulfonyl] [1,1'-biphenyl]-4-yl]methyl] (1-oxobutyl) amino]-1-(diphenylacetyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-71-2 CAPLUS

CN L-Proline, 4-[[[2'-[[(butoxycarbonyl) amino] sulfonyl] [1,1'-biphenyl]-4-yl]methyl] (1-oxobutyl) amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-72-3 CAPLUS

CN L-Proline, 4-[[[2'-[[[3-cyclopentyl-1-oxopropyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-73-4 CAPLUS

CN L-Proline, 4-[[[2'-[[[2-chlorobenzoyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-74-5 CAPLUS

CN L-Proline, 4-[[[2'-[[[(2-methylpropoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, cis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-75-6 CAPLUS

CN L-Proline, 4-[[[2'-[(acetylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-76-7 CAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[[[(1-oxopentadecyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-77-8 CAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[[[(phenylmethoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-78-9 CAPLUS

CN L-Proline, 4-[[[2'-[[[(1,1-dimethylethoxy) carbonyl] amino] sulfonyl] [1,1'-biphenyl]-4-yl] methyl] (1-oxobutyl) amino]-1-(4-pyridinylcarbonyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178866-85-8 CAPLUS

CN L-Proline, 4-[[[2'-[[[(butoxycarbonyl) amino] sulfonyl] [1,1'-biphenyl]-4-yl] methyl] (1-oxobutyl) amino]-1-(4-hydroxybenzoyl)-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 178866-86-9 CAPLUS
 CN L-Proline, 4-[[[2'-[[[3-cyclopentyl-1-oxopropyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-hydroxybenzoyl)-, cis- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 178866-89-2 CAPLUS

CN L-Proline, 4-[[[2'-[[(butoxycarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]-, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178867-84-0P 178867-85-1P 178867-86-2P
 178867-87-3P 178867-88-4P 178868-13-8P
 178868-14-9P 178868-15-0P 178868-16-1P
 178868-17-2P 178868-18-3P 178868-19-4P
 178868-20-7P 178868-21-8P 178868-22-9P
 178868-23-0P 178868-43-4P 178868-44-5P
 178868-45-6P 178868-46-7P 178868-47-8P
 178868-56-9P 178868-57-0P 178868-58-1P
 178868-59-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178867-84-0 CAPLUS

CN L-Proline, 1-(diphenylacetyl)-4-[[[2'-[[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178867-85-1 CAPLUS

CN L-Proline, 1-(diphenylacetyl)-4-[(1-oxobutyl)[[2'-
[[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-,
methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178867-86-2 CAPLUS

CN L-Proline, 4-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]methyl](1-
oxobutyl)amino]-1-(diphenylacetyl)-, methyl ester, cis- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 178867-87-3 CAPLUS

CN L-Proline, 4-[[[2'-[[(butoxycarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(diphenylacetyl)-, methyl ester, cis- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 178867-88-4 CAPLUS

CN L-Proline, 4-[[[2'-[[(3-cyclopentyl-1-oxopropyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(diphenylacetyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-13-8 CAPLUS

CN L-Proline, 1-(4-pyridinylcarbonyl)-4-[[[2'-[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-14-9 CAPLUS

L-Proline, 4-[[[1-oxobutyl][[2'-[[[(triphenylmethyl)amino]sulfonyl][1,1'-
 biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-15-0 CAPLUS

CN L-Proline, 4-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-16-1 CAPLUS

CN L-Proline, 4-[[[2'-[[[(butoxycarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-17-2 CAPLUS

CN L-Proline, 4-[[[2'-[[[3-cyclopentyl-1-oxopropyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-18-3 CAPLUS

CN L-Proline, 4-[[[2'-[[[2-chlorobenzoyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-19-4 CAPLUS

CN L-Proline, 4-[[[2'-[[[(2-methylpropoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-20-7 CAPLUS

CN L-Proline, 4-[[[2'-[(N-acetylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-21-8 CAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[[[(1-oxopentadecyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-22-9 CAPLUS

CN L-Proline, 4-[(1-oxobutyl)[[2'-[[[(phenylmethoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-23-0 CAPLUS

CN L-Proline, 4-[[[2'-[[[(1,1-dimethylethoxy) carbonyl] amino] sulfonyl] [1,1'-biphenyl]-4-yl]methyl] (1-oxobutyl) amino]-1-(4-pyridinylcarbonyl)-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-43-4 CAPLUS

CN L-Proline, 1-[[[6-(methoxymethoxy)-3-pyridinyl] carbonyl]-4-[[[2'-[[[(triphenylmethyl) amino] sulfonyl] [1,1'-biphenyl]-4-yl]methyl] amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-44-5 CAPLUS

CN L-Proline, 1-[[6-(methoxymethoxy)-3-pyridinyl]carbonyl]-4-[(1-oxobutyl)amino][2'-[[[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-45-6 CAPLUS

CN L-Proline, 4-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-[[1,6-dihydro-6-oxo-3-pyridinyl]carbonyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-46-7 CAPLUS

CN L-Proline, 4-[[[2'-[[(butoxycarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl] (1-oxobutyl)amino]-1-[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-47-8 CAPLUS

CN L-Proline, 1-[4-(3-cyclopentyl-1-oxopropoxy)benzoyl]-4-[[[2'-[[(3-cyclopentyl-1-oxopropyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl] (1-oxobutyl)amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-56-9 CAPLUS

CN L-Proline, 1-[[2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]carbonyl]-4-[[[2'-
[[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-,
methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-57-0 CAPLUS

CN L-Proline, 1-[[2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]carbonyl]-4-[(1-
oxobutyl)[2'-[[(triphenylmethyl)amino]sulfonyl][1,1'-biphenyl]-4-
yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-58-1 CAPLUS

CN L-Proline, 4-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-1-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178868-59-2 CAPLUS

CN L-Proline, 4-[[[2'-[(butoxycarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-

yl)methyl](1-oxobutyl)amino]-1-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]-
, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:700759 CAPLUS
 DN 121:300759
 TI Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethanamines
 IN Ashton, Wallace T.; Chang, Linda L.; Greenlee, William J.; Hutchins,
 Steven M.; Rivero, Ralph A.
 PA Merck and Co., Inc., USA
 SO Brit. UK Pat. Appl., 122 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2268743	A1	19940119	GB 1993-14787	19930716
	US 5312820	A	19940517	US 1992-917642	19920717
PRAI	US 1992-917642		19920717		

OS MARPAT 121:300759


AB Carbamoyl and oxycarbonyl derivs. of biphenylmethanamines I (R1 = carboxy, carbamoyl, sulfonyl, etc.; R2, R3 = H, halo, alkyl, etc.; R6 = alkyl, etc.; R8 H, halo, alkyl, etc.; A, B, C, D = CH: or N:; X = O, V = H, alkoxy, etc.) were disclosed as angiotensin-II antagonists with balanced AT1 and AT2 activity useful in the treatment of hypertension and related disorders and ocular hypertension. Specifically claimed example compds. are 1-[N-[[2'-[(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-N-pentylcarbamoyl]indoline (II) or 1-[[2'-[N-(3-chloro-2-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-3-methyl-1-pentyl-3-[2-(trifluoromethyl)phenyl]urea (III). The possible uses of I as antidepressants (no data) and for the treatment of schizophrenia (no data) were mentioned.

IT 159005-38-6P 159005-39-7P 159005-41-1P
 159005-42-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 159005-38-6 CAPLUS

CN Benzamide, 2-chloro-N-[[4'-[[[(2-methyl-4-pyridinyl)[[methyl[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 159005-39-7 CAPLUS

CN Benzamide, 2-chloro-N-[[4'-[[[(2,6-dimethyl-4-pyrimidinyl)[[methyl[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 159005-41-1 CAPLUS

CN Benzamide, 2-chloro-N-[[4'-[[[[[2-chloro-5-[(1-oxopropyl)amino]phenyl]methylamino]carbonyl](2-methyl-4-pyridinyl)amino]methyl]-5-ethyl[1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 159005-42-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2-chlorobenzoyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](2-methyl-4-pyridinyl)-, 2-(trifluoromethyl)phenyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:270134 CAPLUS

DN 120:270134

TI Quinoline and azaquinoline angiotensin II antagonists containing a substituted biphenyl moiety

IN Chakravarty, Prasun K.

PA Merck and Co., Inc., USA

SO Brit. UK Pat. Appl., 150 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	GB 2264710	A1	19930908	GB 1993-3632	19930223
PRAI	US 1992-845881		19920304		
OS	MARPAT 120:270134				

AB The title compds. I [E = CH, N; R1 = H, C1-8 alkyl, C3-8 cycloalkyl, Ph, etc.; R2 = H, C1-8 alkyl, C3-8 cycloalkyl, CN, NO2, C1-4 alkoxy, carbonyl, Ph, etc.; R3, R4 = H, (un)substituted C1-6 alkyl, C1-6 alkoxy, halogen, etc.; R5 = H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl; R6 = H, halogen, NO2, C1-6 alkyl, C1-6 acyloxy, C3-7 cycloalkyl, etc.; R7 = H, halogen, NO2, NH2, C1-4 alkylamino, di(C1-4 alkyl) amino, CF3, aryl, etc.; R8 = (un)substituted sulfonamide, (un)substituted carbonamide, heterocyclyl, etc.; u = 1-3], useful for the treatment of hypertension (no data), ocular hypertension (no data), cognitive dysfunction (no data), anxiety (no data), or depression (no data), are prepared and I-containing formulations presented. Thus, 2-methyl-4-[2'-(aminosulfonyl)(1,1'-biphen-4-yl)methoxy]quinoline was condensed with PhCOCl, producing 2-methyl-4-[2'-[(benzoylamino)sulfonyl][1,1'-biphen-4-yl)methoxy]quinoline.


IT 152811-31-9P 152811-34-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation and angiotensin II antagonist activity of)

RN 152811-31-9 CAPLUS


CN Benzamide, N-[[4'-[(2-methyl-4-quinolinyl)oxy]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 152811-34-2 CAPLUS
 CN Benzamide, N-[[[4'-[[[2-ethyl-6-methoxy-1,5-naphthyridin-4-yl)oxy)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



IT **152811-29-5P 152811-32-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and angiotensin II antagonist activity of, reaction of)
 RN 152811-29-5 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[[2-methyl-4-quinolinyl)oxy)methyl]- (9CI) (CA INDEX NAME)



RN 152811-32-0 CAPLUS
 CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[[2-ethyl-6-methoxy-1,5-naphthyridin-4-yl)oxy)methyl]- (9CI) (CA INDEX NAME)




IT 152811-30-8P 152811-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of angiotensin II antagonists)


RN 152811-30-8 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[2-methyl-4-quinolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 152811-33-1 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[2-ethyl-6-methoxy-1,5-naphthyridin-4-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



10/673,100

=> => d his

(FILE 'HOME' ENTERED AT 17:46:21 ON 01 JUL 2004)

FILE 'REGISTRY' ENTERED AT 17:46:42 ON 01 JUL 2004

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 0 S L3 SSS SAM
L5 0 S L3 SSS FUL
L6 STRUCTURE UPLOADED
L7 0 S L6 SSS SAM
L8 STRUCTURE UPLOADED
L9 39 S L8 SSS SAM
L10 STRUCTURE UPLOADED
L11 3 S L10 SSS SAM
L12 143 S L10 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:59:34 ON 01 JUL 2004

L13 18 S L12

FILE 'CAOLD' ENTERED AT 18:00:25 ON 01 JUL 2004

=> s 112

L14 0 L12

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	409.87

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-13.23

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 18:00:36 ON 01 JUL 2004

This Page Blank (uspto)

This Page Blank (uspto)